Skip to main content

Hepatology News

Research Review
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Drug Safety
01/14/2026
Jessica Garlewicz
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
For practicing...
01/14/2026
Gastroenterology
Research Highlights
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Research Highlights
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology
Research Highlights
10/03/2025
Rebecca Mashaw
By integrating genomic and immunologic perspectives, a recent study reviews ways in which immune dysfunction and genomic alterations may drive tumor initiation, progression, and therapeutic response in cholangiocarcinoma.
By integrating genomic and immunologic perspectives, a recent study reviews ways in which immune dysfunction and genomic alterations may drive tumor initiation, progression, and therapeutic response in cholangiocarcinoma.
By integrating genomic and...
10/03/2025
Gastroenterology
Research Highlights
10/01/2025
Allison Casey
Hepatic arterial infusion pump (HAIP) chemotherapy combined with systemic chemotherapy was associated with a favorable 3-year overall survival compared to systemic chemotherapy alone for patients with advanced intrahepatic cholangiocarcinoma.
Hepatic arterial infusion pump (HAIP) chemotherapy combined with systemic chemotherapy was associated with a favorable 3-year overall survival compared to systemic chemotherapy alone for patients with advanced intrahepatic cholangiocarcinoma.
Hepatic arterial infusion pump...
10/01/2025
Gastroenterology
Research Highlights
10/01/2025
Stephanie Holland
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized,...
10/01/2025
Gastroenterology